Description
A boron-containing macrolide antibiotic; inhibits growth of B. subtilis (MIC = 0.05 µg/ml); decreases the synthesis of protein, RNA, and DNA in B. subtilis at 0.05 µg/ml; inhibits the growth of B. halodurans (MIC = 10 ng/ml); reverses bleomycin-induced cell cycle arrest at the G2 phase in Jurkat cells at 3.4 nM; inhibits replication of the HIV-1 strains LAV-1 and RF and the HIV-2 strain LAV-2 in MT-4 cells (IC50s = 0.008, 0.11, and 0.007 µM, respectively); inhibits replication of a clinical isolate of HIV-1, strain KK-1, in MT-4 cells and PBMCs (IC50s = 0.14 and <0.1 µM, respectively)
Formal name: (T-4)-[(1R)-1-[(1S,2R,5S,6R,8R,12R,14S,17R,18S,19R,22S,24Z,28S,30S,33R)-1,2,18,19-tetra(hydroxy-κO)-12,28-dihydroxy-6,13,13,17,29,29,33-heptamethyl-3,20-dioxo-4,7,21,34,35-pentaoxatetracyclo[28.3.1.15,8.114,18]hexatriacont-24-en-22-yl]ethyl D-valinato(4-)]-borate(1-), monohydrogen
Synonyms: NSC 121380
Molecular weight: 879.9
CAS: 34524-20-4
Purity: ≥98%
Formulation: A solid